Therapeutic Strategies in Advanced Cervical Cancer Detection, Prevention and Treatment.

IF 2.7 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI:10.2147/OTT.S475132

Xolisiwe M Sebutsoe, Nrateng Joyful Nonhlanzeko Tsotetsi, Zodwa Edith Jantjies, Portia Pheladi Raphela-Choma, Mpho S Choene, Lesetja R Motadi

{"title":"Therapeutic Strategies in Advanced Cervical Cancer Detection, Prevention and Treatment.","authors":"Xolisiwe M Sebutsoe, Nrateng Joyful Nonhlanzeko Tsotetsi, Zodwa Edith Jantjies, Portia Pheladi Raphela-Choma, Mpho S Choene, Lesetja R Motadi","doi":"10.2147/OTT.S475132","DOIUrl":null,"url":null,"abstract":"<p><p>Cervical cancer is ranked the fourth most common cause of cancer related deaths amongst women. The situation is particularly dire in low to lower middle-income countries. It continues to affect these countries due to poor vaccine coverage and screening. Cervical cancer is mostly detected in the advanced stages leading to poor outcomes. This review focuses on the progress made to date to improve early detection and targeted therapy using both circulating RNA. Vaccine has played a major role in cervical cancer control in vaccinated young woman in mainly developed countries yet in low-income countries with challenges of 3 dose vaccination affordability, cervical cancer continues to be the second most deadly amongst women. In this review, we show the progress made in reducing cervical cancer using vaccination that in combination with other treatments that might improve survival in cervical cancer. We further show with both miRNA and siRNA that targeted therapy and specific markers might be ideal for early detection of cervical cancer in low-income countries. These markers are either upregulated or down regulated in cancer providing clue to the stage of the cancer.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S475132","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cervical cancer is ranked the fourth most common cause of cancer related deaths amongst women. The situation is particularly dire in low to lower middle-income countries. It continues to affect these countries due to poor vaccine coverage and screening. Cervical cancer is mostly detected in the advanced stages leading to poor outcomes. This review focuses on the progress made to date to improve early detection and targeted therapy using both circulating RNA. Vaccine has played a major role in cervical cancer control in vaccinated young woman in mainly developed countries yet in low-income countries with challenges of 3 dose vaccination affordability, cervical cancer continues to be the second most deadly amongst women. In this review, we show the progress made in reducing cervical cancer using vaccination that in combination with other treatments that might improve survival in cervical cancer. We further show with both miRNA and siRNA that targeted therapy and specific markers might be ideal for early detection of cervical cancer in low-income countries. These markers are either upregulated or down regulated in cancer providing clue to the stage of the cancer.

查看原文本刊更多论文

晚期宫颈癌检测、预防和治疗的治疗策略。

宫颈癌是导致妇女因癌症死亡的第四大常见原因。中低收入国家的情况尤为严重。由于疫苗接种和筛查覆盖率低，宫颈癌继续影响着这些国家。宫颈癌大多在晚期才被发现，导致不良后果。本综述重点介绍迄今为止在利用循环 RNA 改善早期检测和靶向治疗方面取得的进展。在以发达国家为主的接种疫苗的年轻女性中，疫苗在宫颈癌控制中发挥了重要作用，但在低收入国家，由于三剂疫苗接种费用难以承受，宫颈癌仍然是女性中第二大致命癌症。在这篇综述中，我们展示了在利用疫苗接种减少宫颈癌方面取得的进展，疫苗接种与其他治疗方法的结合可能会提高宫颈癌患者的生存率。我们还通过 miRNA 和 siRNA 进一步说明，靶向治疗和特定标记物可能是低收入国家早期检测宫颈癌的理想方法。这些标记物在癌症中上调或下调，为癌症分期提供了线索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.